Metastatic Colorectal Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Metastatic Colorectal Cancer remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 744 matched trial records and 2,148 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700719 | SHR-A1904 | Phase 2; Not yet recruiting | Sponsor not listed | China | Incidence of treatment related adverse event [Safety and Tolerability] (From the initiation of the first dose to 90 days after the last dose); Objective response rate (ORR) (From enrollment to the end of treatment at 6 weeks) | 2027-11-28 |
| NCT07691489 | Fam-trastuzumab deruxtecan-NXKI | Phase 2; Not yet recruiting | Memorial Sloan Kettering Cancer Center | United States | Overall Response Rate (ORR) (Up to 1 year) | 2029-06-01 |
| NCT07693751 | SOT-109 | Phase 1/2; Not yet recruiting | SOTIO Biotech as | United States, Moldova | Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT109 (At the end of Cycle 1 (one cycle is 21 days)); Part B: Optimal dose of SOT109 for subsequent clinical trials (Cycle 1 Day 1 up to 30 days after the last dose (each cycle is 21 days)) | 2027-11-29 |
| NCT07688148 | TAX-2 | Phase 1/2; Not yet recruiting | Apmonia Therapeutics SAS | Belgium, France | Number of patients with DLTs _ Phase 1 (From enrollment to the end of Cycle 1 (each cycle is 28 days)); Safety and tolerability to be determined based on the frequency and number of patients with AEs (From enrollment to the end of Cycle 1 (each cycle is 28 days)) | 2029-02-01 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNDX-5613 in Patients With Colorectal Cancer and Other Solid Tumors (Phase 1/2): the indexed record reports -; -; Phase 1a: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) = 0 Participants.
- A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (Phase 1/2): the indexed record reports -; -; -.
- The Role of Neutrophil Mitochondrial Dysfunction in Medical Rehabilitation During Palliative Chemotherapy for Metastatic Colorectal Cancer (Phase 2/3): the indexed record reports Relative Dose Intensity of FOLFOX(Mean) = 59.7 percentage (Standard Deviation, 18.9); -; Relative Dose Intensity of FOLFOX(Mean) = 78.4 percentage (Standard Deviation, 15.2).
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including SHR-A1904 (Phase 3; CLDN18.2), Fam-trastuzumab deruxtecan-NXKI (Approved; HER2 x Top I), SOT-109 (Phase 1/2; CDH17 x Top I), TAX-2 (Phase 1/2; CD47 x IFNγ x THBS1). Company & Deal Intelligence records identify sponsor context for Memorial Sloan Kettering Cancer Center, SOTIO Biotech as, Apmonia Therapeutics SAS. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Metastatic Colorectal Cancer has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
